Program - 62th Days H.P. Klotz - 2019


    

"New insights into the pathophysiology and treatment of Neuroendocrine Tumors"

Thursday, June 20th, 2019

INTRODUCTION (08:45-09:00) - Luca Persani, Milan, Italie

PRECLINICAL MODELS OF NEUROENDOCRINE TUMORS (9:00-10:30)

Chairs: Luca Persani, Olivier Chabre

  • Relevance of NETs models assessed by kinomic profiling.
    David Romano, Marseille, France
  • Zebrafish.
    Giovanni Vitale, Milan, Italy
  • Preclinical models of neuroendocrine Tumors.
    Natalia Pellegata, Neuherberg, Germany

COFFEE BREAK-POSTERS (10:30-11:15)

PATHOLOGY, GENOMICS AND EPIGENOMICS OF NEUROENDOCRINE TUMORS (11:15-12:45)

Chairs: Jérôme Bertherat, Albert Beckers

  • GEP and thoracic neuroendocrine tumors.
    Aldo Scarpa, Verone, Italy
  • Emerging Molecular Markers of Metastatic Pheochromocytomas and  Paragangliomas.
    Luis Jaime Castro-Vega, Paris, France
  • Epigenomics in neuroendocrine tumors.
    Leo Hofland, Rotterdam, The Netherlands

LUNCH (12:45-14:00)

DIAGNOSIS OF NEUROENDOCRINE NEOPLASMS (14:00-15:30)

Chairs: Philippe Touraine, Delphine Vezzosi

  • Lung and digestive neuroendocrine neoplasms: from WHO classification to biomarker screening: which perspective?
    Jean-Yves Scoazec, Villejuif, France
  • Biomarkers: are hormone validated tumor biomarkers?
    Wouter de Herder, Rotterdam, The Netherlands
  • Receptor Radionuclide imaging for diagnosis and therapy.
    Frédéric Courbon, Toulouse, France

COFFEE BREAK-POSTERS (15:30-16:15)

PROGRESS IN THE DIAGNOSIS AND MANAGEMENT OF GEP NEOPLASMS (16:15-17:15)

Chairs: Bernard Corvillain, Eric Baudin

  • Digestive system mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN).
    Louis De Mestier, Paris, France
  • French and ENETS Consensus Guidelines.
    Guillaume Cadiot, Reims, France

Friday, June 21st, 2019

MEDULLARY THYROID CANCER (09:00-10:30)

Chairs: Patrice Rodien, Dominique Maiter

  • Clinical utility of genetic diagnosis for sporadic and hereditary MTCs.
    Cristina Romei, Pisa, Italy
  • Baseline and stimulated Calcitonin: Thresholds for the diagnosis of medullary thyroid cancer.
    Laura Fugazzola, Milan, Italy
  • State of the art of medical therapies.
    Eric Baudin, Villejuif, France

COFFEE BREAK (10:30-11:00)

MANAGEMENT OF AGGRESSIVE NEUROENDOCRINE NEOPLASMS: NOVEL PERSPECTIVES IN MEDICAL TREATMENT (11:00-12:30)

  • Aggressive GEP neoplasms.
    Romain Coriat, Paris-Cochin, France
  • Aggressive lung and thymic neoplasms.
    Piero Ferolla, Perugia, Italy
  • Malignant Pheochromocytomas and paragangliomas.
    Julien Hadoux, Villejuif, France

LUNCH (12:30-14:00)

DEBATE ON THE TREATMENT OF GEP NEOPLASMS (14:00-15:00)

Chairs: Vincent Rohmer, Sébastien Gaujoux

  • Role of surgery.
    Alain Sauvanet. Paris, France
  • Role of radiofrequency ablation.
    Marc Barthet. Marseille, France

MULTIPLE ENDOCRINE NEOPLASIA TYPE 1 (15:00-16:30)

  • Update on phenotypes of MEN1 mutation carriers.
    Gerlof Valk, Utrecht, The Netherlands
  • ROUND TABLE DISCUSSION: Clinical screening of MEN1 mutations carriers: When and how screening should be performed ?
    Discussants: Brigitte Delemer, Reims; Catherine Cardot, Lille; Antoine Tabarin, Bordeaux, France

CONCLUSION (16:30-16:45) - Philippe Chanson, Paris, France

© SFE Mai 2019

En poursuivant votre navigation, vous acceptez l'utilisation de cookies. En savoir plus

Fermer